TapewireFind a company

person · Reporting owner

KOBLISH ANTONY

Disclosed activity across 1 company

Tapewire entity
64913
SEC CIK
0001195881

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TELA Bio, Inc.TELA · Entity 7381Director · Chief Executive OfficerFebruary 20, 2026February 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TELA Bio, Inc.

Report date February 20, 2026 · Filed February 24, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect766,110 Reported balance After 2026-02-20 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2026-02-20 · Grant · Acquired 176,000 · Balance 766,110

F1: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.

Common StockSEC Table I · non-derivativeDirect753,616 Reported balance After 2026-02-21 transaction · row 2 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 2 · 2026-02-21 · Tax withholding · Disposed 12,494 · Balance 753,616

F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Common StockSEC Table I · non-derivativeDirect741,985 Reported balance After 2026-02-23 transaction · row 3 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 3 · 2026-02-23 · Tax withholding · Disposed 11,631 · Balance 741,985

F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Common StockSEC Table I · non-derivativeDirect586,210 Reported balance After 2026-02-24 transaction · row 4 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 4 · 2026-02-24 · Tax withholding · Disposed 3,900 · Balance 586,210

F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2036-02-20Direct261,000 Reported balance After 2026-02-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-02-20 · Grant · Acquired 261,000 · Balance 261,000

F3: The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.

F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

F3: The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 24, 2026 Filed Feb 24, 2026 20:01 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 3,900 $0.79 $3,062.28
Disclosure

SEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 4

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 586,210

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 23, 2026 Filed Feb 24, 2026 20:01 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 11,631 $0.77 $8,909.35
Disclosure

SEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 3

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 741,985

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 21, 2026 Filed Feb 24, 2026 20:01 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 12,494 $0.72 $8,963.20
Disclosure

SEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 2

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 753,616

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 20:01 UTC TELA Bio, Inc. TELA · Entity 7381 GrantStock Option (Right to Buy) · Derivative 261,000 $0.00 Strike: $0.72 $0.00
Disclosure

SEC source: 0001195881-26-000002 · form4-02252026_010251.xml · derivative · entry 5

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,000

Underlying: Common Stock · 261,000 shares

Expires 2036-02-20

F3 · derivative.exercise_date: The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 20:01 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock 176,000 $0.00 $0.00
Disclosure

SEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 766,110

F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 16:45 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 384 $1.22 $468.48
Disclosure

SEC source: 0001062993-25-006859 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590,110

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 24, 2025 Filed Feb 25, 2025 16:57 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 5,772 $2.65 $15,295.80
Disclosure

SEC source: 0001062993-25-003497 · form4.xml · nonDerivative · entry 3

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590,494

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 23, 2025 Filed Feb 25, 2025 16:57 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 11,631 $2.72 $31,636.32
Disclosure

SEC source: 0001062993-25-003497 · form4.xml · nonDerivative · entry 2

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 596,266

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 16:57 UTC TELA Bio, Inc. TELA · Entity 7381 GrantStock Option (Right to Buy) · Derivative 219,000 $0.00 Strike: $2.72 $0.00
Disclosure

SEC source: 0001062993-25-003497 · form4.xml · derivative · entry 4

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,000

Underlying: Common Stock · 219,000 shares

Expires 2035-02-21

F3 · derivative.exercise_date: The option vests 25% on February 21, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 16:57 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock 149,000 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-003497 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 607,897

F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 21, 2026, subject to the Reporting Person's continuous service through the applicable vesting dates.

Read SEC document
October 24, 2024 Filed Oct 24, 2024 16:25 UTC TELA Bio, Inc. TELA · Entity 7381 PurchaseCommon Stock 88,888 $2.25 $199,998.00
Disclosure

SEC source: 0001062993-24-017928 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 458,897

F1 · kind: The shares were purchased in the Issuer's underwritten public offering that closed on October 24, 2024, at the public offering price of $2.25 per share.

Read SEC document
March 31, 2024 Filed Apr 2, 2024 19:44 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 385 $5.67 $2,182.95
Disclosure

SEC source: 0001062993-24-007842 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 370,009

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 24, 2024 Filed Feb 27, 2024 16:36 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 5,726 $7.07 $40,482.82
Disclosure

SEC source: 0001062993-24-004581 · form4.xml · nonDerivative · entry 3

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 370,394

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 16:36 UTC TELA Bio, Inc. TELA · Entity 7381 GrantStock Option (Right to Buy) · Derivative 113,200 $0.00 Strike: $7.07 $0.00
Disclosure

SEC source: 0001062993-24-004581 · form4.xml · derivative · entry 4

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,200

Underlying: Common Stock · 113,200 shares

Expires 2034-02-23

F3 · derivative.exercise_date: The option vests 25% on February 23, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 16:36 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 5,014 $7.07 $35,448.98
Disclosure

SEC source: 0001062993-24-004581 · form4.xml · nonDerivative · entry 2

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,120

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 16:36 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock 77,500 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-004581 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 381,134

F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 23, 2025, subject to the Reporting Person's continuous service through the applicable vesting dates.

Read SEC document
November 14, 2023 Filed Nov 14, 2023 20:01 UTC TELA Bio, Inc. TELA · Entity 7381 PurchaseCommon Stock 11,000 $4.54 $49,976.30
Disclosure

SEC source: 0001062993-23-020847 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,634

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions ranging from $4.49 to $4.55. The Reporting Person undertakes to provide TELA Bio, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 18:03 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 385 $10.64 $4,096.40
Disclosure

SEC source: 0001062993-23-008668 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 292,634

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 24, 2023 Filed Feb 27, 2023 19:16 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 6,034 $11.03 $66,555.02
Disclosure

SEC source: 0001062993-23-005025 · form4.xml · nonDerivative · entry 2

KOBLISH ANTONY · CIK 0001195881 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 293,019

F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.

Read SEC document
February 23, 2023 Filed Feb 27, 2023 19:16 UTC TELA Bio, Inc. TELA · Entity 7381 GrantStock Option (Right to Buy) · Derivative 96,100 $0.00 Strike: $10.50 $0.00
Disclosure

SEC source: 0001062993-23-005025 · form4.xml · derivative · entry 3

KOBLISH ANTONY · CIK 0001195881 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,100

Underlying: Common Stock · 96,100 shares

Expires 2033-02-23

F3 · derivative.exercise_date: The option vests 25% on February 23, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Read SEC document
February 23, 2023 Filed Feb 27, 2023 19:16 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock 61,200 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-005025 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,053

F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 23, 2024, subject to the Reporting Person's continuous service through the applicable vesting dates.

Read SEC document
March 31, 2022 Filed Apr 1, 2022 16:43 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 384 $11.63 $4,465.92
Disclosure

SEC source: 0001062993-22-009221 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,853

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
February 24, 2022 Filed Feb 25, 2022 17:11 UTC TELA Bio, Inc. TELA · Entity 7381 GrantStock Option (Right to Buy) · Derivative 79,500 $0.00 Strike: $11.98 $0.00
Disclosure

SEC source: 0001062993-22-005780 · form4.xml · derivative · entry 2

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,500

Underlying: Common Stock · 79,500 shares

Expires 2032-02-24

F2 · derivative.exercise_date: The option vests 25% on February 24, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Read SEC document
February 24, 2022 Filed Feb 25, 2022 17:11 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock 46,500 $0.00 $0.00
Disclosure

SEC source: 0001062993-22-005780 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,924

F1 · shares: These restricted stock units will vest in four equal annual installments beginning on February 24, 2023, subject to the Reporting Person's continuous service through the applicable vesting dates.

Read SEC document
February 24, 2022 Filed Feb 28, 2022 16:21 UTC TELA Bio, Inc. TELA · Entity 7381 Tax withholdingCommon Stock 2,687 $11.98 $32,190.26
Disclosure

SEC source: 0001062993-22-005907 · form4.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,237

F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Read SEC document
March 31, 2021 Filed Apr 2, 2021 14:43 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock 5,439 $0.00 $0.00
Disclosure

SEC source: 0001192482-21-000300 · edgar.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,424

F1 · shares: These restricted stock units will vest in four equal annual installments beginning on March 31, 2022, subject to the Reporting Person's continuous service with the Issuer.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 17:31 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock (right to buy) · Derivative 63,600 $0.00 Strike: $16.99 $0.00
Disclosure

SEC source: 0001192482-21-000192 · edgar.xml · derivative · entry 2

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,600

Underlying: Common Stock · 63,600 shares

Expires 2031-02-24

F2 · derivative.exercise_date: The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 17:31 UTC TELA Bio, Inc. TELA · Entity 7381 GrantCommon Stock 34,900 $0.00 $0.00
Disclosure

SEC source: 0001192482-21-000192 · edgar.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,985

F1 · shares: These restricted stock units will vest in four equal annual installments beginning on February 24, 2022, subject to the Reporting Person's continuous service with the Issuer.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 21:09 UTC TELA Bio, Inc. TELA · Entity 7381 ConversionWarrant (right to buy) · Derivative 10,775 $0.00 Strike: $28.65 $0.00
Disclosure

SEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 6

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,775

Underlying: Common Stock · 436 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 21:09 UTC TELA Bio, Inc. TELA · Entity 7381 ConversionWarrant (right to buy) · Derivative 10,775 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 5

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 10,775 shares

Expires 2027-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 21:09 UTC TELA Bio, Inc. TELA · Entity 7381 ConversionSeries B Preferred Stock · Derivative 351,271 $0.00 $0.00
Disclosure

SEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 4

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,225 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 21:09 UTC TELA Bio, Inc. TELA · Entity 7381 ConversionSeries A Preferred Stock · Derivative 179,685 $0.00 $0.00
Disclosure

SEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 3

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,277 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 21:09 UTC TELA Bio, Inc. TELA · Entity 7381 ConversionCommon Stock 14,225 Not disclosed Not disclosed
Disclosure

SEC source: 0001192482-19-000434 · edgar.xml · nonDerivative · entry 2

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,085

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 21:09 UTC TELA Bio, Inc. TELA · Entity 7381 ConversionCommon Stock 7,277 Not disclosed Not disclosed
Disclosure

SEC source: 0001192482-19-000434 · edgar.xml · nonDerivative · entry 1

KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,860

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · balance_after: Reflects 16,273 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.